Adenovirus Vaccines

Barr Awarded $35 Million Department Of Defense Contract

Published in TB and Outbreaks Week, October 23rd, 2001

Barr Laboratories, Inc. announced September 28, 2001, that it has been awarded a $35.4 million, six-year contract from the United States Department of Defense for development of adenovirus vaccines type 4 and 7.

Barr officials said that the contract provides $17.4 million to support Phase I development, and $18 million to support Phase II and Phase III clinical studies and the filing of the biological license applications. Following successful approval, Barr would manufacture the vaccines under contract to the government specifically for dispensing to the armed forces.

"We are excited about the opportunity to work with Walter Reed Army Institute of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2001-10-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry